PolandPoland

Struggling Bioton looks forward

20.09.2009

Warsaw – Polish insulin, antibiotics, and biosimilar producer Bioton SA has doubled its second-quarter net loss to PLN39m (–EUR9.3m) because sales fell by 8% in the period from April to June. The company, which is restructuring after a management change in January (see EuroBiotechNews 1-2/2009), took an operating loss of PLN49m (–EUR11.7m) in the first half of the year after a profit of PLN24m (+EUR5.7m) million a year ago. The result was within the range of what analysts had expected.
Bioton, which is looking to strengthen its presence in the key insulin markets of China and India through cooperation agreements, plans to lauch new bio­technological products by 2012 that have been developed by its Swiss subsi­diary Biopartners. In the course of the restructuring process, 25% of Biopartners staff has been cut compared to 2008. Bio­ton also said it is in licensing talks with big pharma companies concerning the subsidiary’s biosimilar pipeline, which currently consists of interferon beta and human growth hormone (hGH SR). There are also ongoing discussions about the best way to commercialise Biopartners’ interferon beta biosimilar Biferonex, including applications in the US and Australian markets and re-submission to the European Medicines Agency. Bioton estimates the annual EU market for human growth hormone at a400m, and that for interferon beta at about EUR1.2bn.

PolandPoland

07.03.2012

Polish antibody development and manufacturing specialist Mabion S.A. more than tripled its revenues in 2011 (€2.5m) compared to 2010 (€0.74m). The increase in turnover mainly resulted from stronger client demand for R&D services...

PolandPoland

01.03.2012

Polish company Bioton S.A (Warsaw) and Swiss-headquartered generics giant Actavis (Zug) have joined forces to shake up the €12bn world market for recombinant insulins and insulin analogues. At the end of January, Bioton Chairman...

PolandPoland

31.01.2012

Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes drugs. Swiss Actavis and Bioton from Warsaw announced that they have formed a joint venture company for the...

PolandPoland

10.12.2011

Krakow – Polish Selvita S.A., which offers preclinical drug development services to pharma companies, has been ranked as the No. 1 “Rising Star” of this year’s Fast50 contest. In the programme, analysts from Deloitte Technology...

PolandPoland

09.12.2011

Warsaw – Poland’s Bioton S.A. has announced it is investing €20m in a new production plant in Szczecin. The biotechnology company is planning to manufacture insulin injection devices in the facility. The project involves the...

PolandPoland

01.10.2011

Warsaw – Biotech experts want to make the development of pharmaceutical and medical innovations a priority in Poland. At the start of September, members of the Polish Technology Platform for Innovative Medicine recommended that...

PolandPoland

02.08.2011

Kraków – Selvita SA CEO Pawel Przewiezlikowski announced at the end of July that the Polish drug development and drug discovery service firm is close to achieving profitability. After bagging EUR3.7m through an IPO on Warsaw’s...

PolandPoland

12.06.2011

Warsaw – Researchers from Lodz and Poznan Universities say Poland needs to update its draft GMO law. “The national current legal situation is complicated,” Prof. Tomas Twardowski told EuroBiotechNews, stressing that while trade...

PolandPoland

12.06.2011

Krakow – Polish Selvita S.A. is going public. By May, the drug discovery specialist announced it had entered into definite agreements with investors to sell 2.7 million shares for a total of EUR3.75m, resulting in a market...

PolandPoland

11.06.2011

Szczecin/Greifswald – A team of physical chemists headed by Robert Hoylst from the Polish Academy of Science have improved a method for calculating the migration time of drugs or drug delivery devices introduced into the sol/gel...

Displaying results 1 to 10 out of 108

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-poland/article/struggling-bioton-looks-forward.html

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • PROTHENA PLC (IE)18.44 USD6.84%
  • WILEX (D)3.28 EUR5.47%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • HYBRIGENICS (F)1.71 EUR-8.56%

TOP

  • WILEX (D)3.28 EUR331.6%
  • SANTHERA (CH)69.50 CHF133.2%
  • ADDEX (CH)4.21 CHF95.8%

FLOP

  • MERCK KGAA (D)63.45 EUR-50.2%
  • THROMBOGENICS (B)8.55 EUR-40.5%
  • HYBRIGENICS (F)1.71 EUR-34.5%

TOP

  • SANTHERA (CH)69.50 CHF3375.0%
  • GW PHARMACEUTICALS (UK)415.25 GBP765.1%
  • SKYEPHARMA PLC (UK)260.00 GBP314.3%

FLOP

  • CYTOS (CH)0.27 CHF-92.1%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.55 EUR-72.1%

No liability assumed, Date: 22.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events